Spindle Cell Sarcoma
Associated Genetic Biomarkers
NCI Definition: A malignant mesenchymal neoplasm composed of spindle-shaped cells. This is a morphologic term which can be applied to a wide range of sarcomas. 
Spindle cell sarcomas most frequently harbor alterations in MDM2, CDK4, TERT, PDGFRA, and KIT .
MDM2 Amplification, CDK4 Amplification, PDGFRA Amplification, KIT Amplification, and TERT Amplification are the most common alterations in spindle cell sarcoma .
There are 2 clinical trials for spindle cell sarcoma, of which 2 are open and 0 are completed or closed. Of the trials that contain spindle cell sarcoma as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).
Ganglioside is the most frequent gene inclusion criterion for spindle cell sarcoma clinical trials .
Bo-112, hu3f8-bsab, and nivolumab are the most common interventions in spindle cell sarcoma clinical trials.
Significant Genes in Spindle Cell Sarcoma
MYCN is an inclusion eligibility criterion in 1 clinical trial for spindle cell sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and spindle cell sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.